Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Mutations in EPHB4 cause human venous valve aplasia
Oliver Lyons, … , Prakash Saha, Alberto Smith
Oliver Lyons, … , Prakash Saha, Alberto Smith
Published August 17, 2021
Citation Information: JCI Insight. 2021;6(18):e140952. https://doi.org/10.1172/jci.insight.140952.
View: Text | PDF
Research Article Angiogenesis Development

Mutations in EPHB4 cause human venous valve aplasia

  • Text
  • PDF
Abstract

Venous valve (VV) failure causes chronic venous insufficiency, but the molecular regulation of valve development is poorly understood. A primary lymphatic anomaly, caused by mutations in the receptor tyrosine kinase EPHB4, was recently described, with these patients also presenting with venous insufficiency. Whether the venous anomalies are the result of an effect on VVs is not known. VV formation requires complex “organization” of valve-forming endothelial cells, including their reorientation perpendicular to the direction of blood flow. Using quantitative ultrasound, we identified substantial VV aplasia and deep venous reflux in patients with mutations in EPHB4. We used a GFP reporter in mice to study expression of its ligand, ephrinB2, and analyzed developmental phenotypes after conditional deletion of floxed Ephb4 and Efnb2 alleles. EphB4 and ephrinB2 expression patterns were dynamically regulated around organizing valve-forming cells. Efnb2 deletion disrupted the normal endothelial expression patterns of the gap junction proteins connexin37 and connexin43 (both required for normal valve development) around reorientating valve-forming cells and produced deficient valve-forming cell elongation, reorientation, polarity, and proliferation. Ephb4 was also required for valve-forming cell organization and subsequent growth of the valve leaflets. These results uncover a potentially novel cause of primary human VV aplasia.

Authors

Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith

×

Figure 2

Expression of EphB4 in Efnb2GFP reporter E18 and P0.

Options: View larger image (or click on image) Download as PowerPoint
Expression of EphB4 in Efnb2GFP reporter E18 and P0.
(A) Localization of...
(A) Localization of PECAM1 (blue), Ephb4 (magenta), Prox1 (white), and Efnb2:GFP (green) in heterozygous Efnb2GFP mice on E18. Part of an E18 VV is shown, and the white boxed area (which contains organizing VFCs) is shown enlarged in single channel images. Only the anterior vein wall is shown. Arrowhead indicates a VFC nearer the inferior edge of the vessel coexpressing Ephb4 and Efnb2GFP. The schematic indicates stages 0 and 1 of VV development, as previously defined in ref. 11. Red = Prox1hi VFCs, which form a continuous line across the anterior vein wall at stage 1. The orientation of all confocal Z stacks is indicated and is the same throughout all figures. (B) An XZ projection (13.6-μm deep) and the fluorescence intensity profile for Efnb2GFP and EphB4 are shown across the organizing VFCs, indicated by the yellow boxed area in A. The EphB4 signal is stronger upstream (to the left) of the VFCs (indicated by arrowheads, or “0” on the graph x axis), whereas the Efnb2GFP signal is stronger in VFCs and downstream (P < 0.0001, n = 6 VVs, 2-tailed t test). The multichannel image does not include Prox1. (C) In WT VVs on P0, Prox1hi VFCs expressed EphB4, and it was particularly strongly expressed in the superior and inferior areas of the vein (arrowheads). (D) Coexpression of Ephb4 and Efnb2 was confirmed in Efnb2GFP mice. Z projections (6 μm) of the upper and lower regions of a valve are shown. Arrowheads indicate reorientated VFCs (orange). (Uncropped images are provided in Supplemental Figure 2B.) Scale bars: 20 μm. VFCs, valve-forming cells; VVs, venous valves; E18, embryonic day 18; P0, postnatal day 0.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts